Clinical Trials Logo

Lung Cancer Metastatic clinical trials

View clinical trials related to Lung Cancer Metastatic.

Filter by:

NCT ID: NCT03706287 Recruiting - Clinical trials for Lung Cancer Metastatic

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Start date: December 6, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of vascular endothelial growth factor receptor 2(VEGFR)、FGFR(fibroblast growth factor receptor), platelet-derived growth factor receptor(PDGFR) and tumor cell proliferation related kinase c-Kit, combined with platinum plus pemetrexed in T790M mutation negative metastatic non-squamous non-small cell lung cancer(NSCLC) after the failure of EGFR-TKI.

NCT ID: NCT03703596 Not yet recruiting - Lung Cancer Clinical Trials

Anlotinib Versus Docetaxel as the Second-line Treatment in EGFR Wild Type Patients With Advanced NSCLC

Start date: October 16, 2018
Phase: Phase 2
Study type: Interventional

This study is conducted to explore the safety and efficacy of anlotinib, a tyrosine kinase inhibitors of Vascular Endothelial Growth Factor Receptor 2(VEGFR)、FGFR(Fibroblast Growth Factor Receptor), Platelet-derived growth factor Receptor(PDGFR) and c-kit, vs docetaxel in advanced Non-squamous Non-small cell lung cancer harbouring wild-type epidermal growth factor receptor (EGFR) .

NCT ID: NCT03693339 Recruiting - Cancer Clinical Trials

Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation

Start date: October 30, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II, single-arm, open label study under an umbrella trial for NSCLC. This clinical study is targeted for the patients who harbor exon 14 skipping mutation of MET and all patients will be treated with Capmatinib. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 28 days.

NCT ID: NCT03693326 Recruiting - Cancer Clinical Trials

PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or no Actionable Genetic Abnormalities

Start date: November 1, 2018
Phase: Phase 2
Study type: Interventional

This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.

NCT ID: NCT03638765 Not yet recruiting - Brain Metastases Clinical Trials

Dendritic Cell Therapy for Brain Metastases From Breast- or Lung Cancer

Start date: November 2018
Phase: Phase 1
Study type: Interventional

The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer or breast cancer. The primary objective of the study is to evaluate the safety and feasibility of administering DCVax-Direct to patients with metastatic tumors in the brain. The secondary objectives are to determine tumor response, the rate of intracranial recurrence (IR), the rate of neurologic deaths, decline in neuro-cognitive functioning and overall survival. Approximately 10 patients with injectable metastatic brain tumors will be enrolled initially in a dose escalation scheme, with the expectation to enroll a total of 24 patients.

NCT ID: NCT03595813 Active, not recruiting - Clinical trials for Non Hodgkin Lymphoma

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

IMMUNO-SUP
Start date: January 29, 2018
Phase: N/A
Study type: Interventional

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

NCT ID: NCT03543306 Recruiting - Cancer Clinical Trials

Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation

Start date: June 30, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib and trametinib in stage IV disease to subjects with BRAF V600E mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event.

NCT ID: NCT03439696 Completed - Lung Cancer Clinical Trials

Needlescopic-assisted Uniportal vs Uniportal VATS

UNeed
Start date: February 22, 2018
Phase: N/A
Study type: Interventional

The investigators' study aims is to evaluate the safety and efficacy of uniportal VATS under assistance of needlescopic instruments through additional 2-3 mm ports compared to conventional uniportal VATS in patients with lung lesions.

NCT ID: NCT03400748 Terminated - Lung Cancer Clinical Trials

ANET Electrosurgery Applicator Pilot Evaluation Study

Start date: April 23, 2018
Phase: N/A
Study type: Interventional

Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.

NCT ID: NCT03344861 Completed - Lung Cancer Clinical Trials

Safety of PDT-Photofrin® Prior to Lung Surgery

Start date: August 14, 2017
Phase: Phase 1
Study type: Interventional

This research study is being conducted to assess the safety of PDT in subjects with peripherally located malignant tumors in lung parenchyma prior to surgical resection. It will involve up to 10 sites in USA. Participation will last 4 months.